Case Management Order Outlines Xarelto Lawsuit Bellwether Trial Selection Process

December 02, 2015 – – BloodThinnerHelp.com reports on recent announcements that bellwether selection for the trials consolidated in Xarelto multidistrict litigation number 2592 are now underway. A case management order from United States District Judge Eldon Fallon dated November 20th outlined the criteria for selecting these trials. Several cases will now be chosen for inclusion in a bellwether discovery pool. These cases are generally chosen based on which appear to be most ready for trial. Initially, the judge asked that both plaintiffs and defendants work together to determine the cases selected for the bellwether pool, however, when they were unable to agree on criteria for their selections, the Judge stepped forward to complete the task.

As requested, a total of 40 cases will be chosen to include in the bellwether pool. At this time, plaintiffs and defendants will each select 10 cases, and the remaining cases will be randomly selected. It has been announced by the judge as well that half of the selected cases will be from the Eastern District of Louisiana, while 7 will be from states selected by the defendants and 7 will be from states selected by the plaintiffs. Additionally, 2 cases in the pool will be from Texas federal court and 4 will be from Mississippi federal court. These states chosen must have had at least 20 eligible cases filed concerning the pending litigation.

The lawsuits consolidated in the MDL all similarly allege that Xarelto can cause episodes of dangerous and sometimes fatal uncontrollable bleeding. Xarelto has become widely considered the most dangerous blood thinner on the market due to the fact that it has no corresponding antidote. This means that if a patient using Xarelto is injured and bleeds, physicians will be unable to get that patient’s blood to clot. In these instances, doctors have to resort to extreme life-saving measures such as blood transfusions. For someone taking a traditional blood thinner, however, there is an antidote available through vitamin K. If an individual taking a traditional blood thinner is injured and bleeding, doctors can treat them with vitamin K, reversing the medicine’s effects and successfully clotting their blood.

The quickly approaching status conference for the Xarelto MDL is set for December 21st, 2015. Judge Fallon has asked that parties involved get together between now and then in order to set the eligibility criteria for case selection and to plan case categories. Additionally, they have been asked to plan selection for the initial 4 cases to go to trial. It is expected that the first trial dates for these cases may be between February and May of 2017.

At this time, the MDL includes over 2,800 cases alleging that defendants Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG neglected to provide an antidote for their drug and neglected to properly warn consumers of the significant dangers associated with Xarelto use.

As these cases await trial and continue to grow rapidly in number, Attorney Joseph Osborne is working to ensure that individuals who have experienced adverse health effects after using Xarelto have the opportunity to investigate their legal rights. These people may be entitled to significant compensation. Attorney Osborne is currently offering free legal consultations to those involved.

To request additional information regarding Xarelto bleeding lawsuits or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60005957